GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT: The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers’ race to bolster pipelines. #GSK #Nuvalent #Biotech #PharmaDeal #DrugDevelopment


Discover more from umlegacypress

Subscribe to get the latest posts sent to your email.

Leave a Reply

Discover more from umlegacypress

Subscribe now to keep reading and get access to the full archive.

Continue reading